Indian drugmaker, Dr Reddy’s Laboratories, said it had isolated all its data centre services as a preventive measure following a cyberattack. Its plants in the United States, United Kingdom, Brazil, India and Russia were impacted.
“We are anticipating all services to be up within 24 hours and we do not foresee any major impact on our operations due to this incident,” Dr Reddy’s Chief Information Officer, Mukesh Rathi, said in a statement.
Dr. Reddy’s Laboratories and Russian Direct Investment Fund received approval from the Drugs Controller General of India to conduct an adaptive phase 2/3 human clinical trial for Sputnik V COVID-19 vaccine in India.
Javvad Malik, Security Awareness Advocate at KnowBe4, said: “The pharmaceutical and medical industry has had an intense spotlight shone on it ever since research began to try and find a vaccine for the Coronavirus. We’ve seen many research labs targeted by nation states with many using spearphishing to infiltrate organisations.”
Click below to share this article
